Comments
Zydus Lifesciences Ltd, on Tuesday, announced that the cGMP inspection by the US drug regulator, US Food and Drug Administration (USFDA), was concluded with nil observations.
In a statement on Tuesday, Zydus said, “The group’s injectables manufacturing facility at Zydus Biotech Park in Changodar, Ahmedabad, underwent USFDA inspection from June 5 to June 13, 2023. The cGMP inspection concluded with nil observations.”
Also read: Zydus Lifesciences initiates Phase-IV trial for Saroglitazar Mg in NAFLD patients
Zydus Lifesciences shares ended with gains of 1.5% on NSE to close at ₹517.65 on Tuesday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.